To evaluate whether FGFR1 upregulation occurs in clinical NSCLC tumors that progressed on EGFR-TKI treatment, we examined the FGFR1 mRNA expression in paired tumor samples from EGFR-mutant NSCLC patients at baseline and after progression to EGFR-TKI treatment (Fig. 6f). Here, EGFR is linked to non-small cell lung carcinoma.